A place on the formulary for SSRIs in the treatment of depression

Drugs and Therapy Perspectives

Volumn 8, Issue 6, 1996, Pages 13-16

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; FLUOXETINE; IMIPRAMINE; LOFEPRAMINE; MOCLOBEMIDE; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

CARDIOVASCULAR DISEASE; COST; DEPRESSION; DRUG COST; DRUG FORMULARY; DRUG INDICATION; DRUG INFORMATION; GASTROINTESTINAL TOXICITY; HUMAN; NEUROTOXICITY; PATIENT COMPLIANCE; PRESCRIPTION; QUALITY OF LIFE; SHORT SURVEY; SUICIDE;

EID: 0029758327     PISSN: 11720360     EISSN: None     Source Type: Journal    
DOI: 10.2165/00042310-199608060-00005     Document Type: Short Survey

References (28)

1. GHC to give SSRIs equal status for depression. Disease Management News 1996 Jul 10; 1: 8
2. Hotopf M, Lewis G, Normand C. Are SSRIs a cost-effective alternative to tricyclics? Br J Psychiatry 1996 Apr; 1688: 404-9
3. Wells KB, Katon W, Rogers B, et al. Use of minor tranquilizers and antidepressant medications by depressed outpatients: results from the medical outcomes study. Am J Psychiatry 1994; 151: 694-700
4. Guze BH. Selective serotonin reuptake inhibitors: assessment for formulary inclusion. PharmacoEconomics 1996 May; 9 (5): 430-42
5. British National Formulary No. 31. London: The Pharmaceutical Press, 1996 Mar: 172-8
6. 1995 Physicians GenRx. St Louis, Missouri: Mosby-Year Book, Inc., 1995: 861-5, 1062-5 & 1959-62
7. Lonnqvist J, Sintonen H, Syvüalahti E, et al. Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psychiatr Scand 1994 Jun; 89: 363-9
8. New antidepressants - gold standard or gold mine? Fremantle Hospital Drug Bulletin 1995 Dec; 19 (4): 14-7
9. Greenberg PE, Stiglin LE, Finkelstein SN. The economic burden of depression in 1990 J Clin Psychiatry 1993; 54: 405-18
10. Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993; 7: 191-5
11. Jönsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665-73
12. West R. Depression. London: Office of Health Economics, 1992
13. Mintz J, Mintz IL, Arruda M. Treatment of depression and the functional capacity to work. Arch Gen Psychiatry 1992; 49: 761-8
14. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990; 51: 60-9
15. Katzelnick DJ, Kobak KA, Jefferson JW, et al. Prescribing patterns of antidepressant medications for depression in a HMO. Formulary 1996 May; 31: 374-6, 379-80 & 386-8
16. Donoghue JM, Tylee A. The treatment of depression: prescribing patterns of antidepressants in primary care in the UK. Br J Psychiatry 1996 Feb; 168: 164-8
17. Leow CC, Peterson GM, Jestrimski KW. Review of use of newer antidepressants. Aust J Hosp Pharm 1994; 24: 250-2
18. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants JAMA 1996 Jun 26; 275: 1897-902
19. Johnson DAW. Noncompliance with antidepressant therapy - an underestimated problem. Intern Med 1986; 11: 14-7
20. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Br J Med 1993 Mar 13; 306: 683-7
21. Revicki DA, Brown RE, Palmer W, et al. Modelling the cost effectiveness of antidepressant treatment in primary care. PharmacoEconomics 1995 Dec; 8: 524-40
22. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. Br Med J 1995 Jan 28; 310: 221-4
23. Jick SS, Dean AD, Jick H. Antidepressants and suicide, Br Med J 1995 Jan 28; 310: 215-8
24. Antidepressants and suicide [letters]. Br Med J 1995 Jul 1; 311: 55-7
25. Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement. Br Med J 1992 Nov 14; 305: 1198-202
26. Le Penn C, Levy E, Ravily V, et al. The cost of treatment dropout in depression: a cost-benefit analysis of fluoxetinc vs tricyclics. J Affect Disord 1994 May; 31: 1-18
27. Freemantle N, House A, Song F, et al. Prescribing selective serotonin reuptake inhibitors a strategy for prevention of suicide. Br Med J 1994; 309: 249-53
28. Souêtre E, Martin P, Lozet H, et al. Quality of life in depressed patients: comparison of fluoxetine and major tricyclic antidepressants. Psychopharmacology 1996 Mar; 11: 45-52